SirtSix

Using science to create medicines to help people

[SirtSix @SirtSix]

Best clinical anecdote of the year so far:

Cancer patient goes into spontaneous remission after COVID-19 infection

😮

[SirtSix @SirtSix]

Seeing a lot of people sharing this article and complaining about big pharma causing high drug costs… while working at institutions where Neulasta is marked-up 300% or a PET scan costs > $10k 🤔

https://t.co/svg5I06ALL

[SirtSix @SirtSix]

@BiotechElmo @Biopharmaddict @OxAnalyst ATTRibute-CM topline PR going to begin: "Tell me, O Muse, of that drug Acoramidis and its many winding benefits in all cause mortality and cardiovascular hospitalization"

[SirtSix @SirtSix]

Just gonna skip the postdoc and go straight to a TT position at an R1 school.

[Guy R @grohkin]

This PhD simulator is anxiety-inducing but i cant stop rolling the dice https://t.co/6O6KX2KKKU

[SirtSix @SirtSix]

@ablT315I @JacobPlieth More like a story of, whoops our drug doesn't work by its proposed MOA. But hey, phosphorothioates have known myelotox, let's run MDS and MPN trials!

[SirtSix @SirtSix]

@sentivcapital @bradloncar @BiotechTVHQ Are they really considering doing an ex-US superiority trial for wAMD (OTX-TKI vs. a sub-standard anti-VEGF regimen)? How would that help them?

[SirtSix @SirtSix]

@BiotechElmo @Biohazard3737 @buysidebio Yeah... interesting idea but lots of questions for a tech like this.

Can one bait capture the diversity of autoreactive clones (combat epitope spreading)?

Risk of actually generating an ADA response?

Is ASGPR really the right target for directing efficient degradation?

[SirtSix @SirtSix]

@PTarantinoMD Doubt the authors would agree with the characterization of their drug as “non-targeted”.

Plenty of data flies in the face of the idea that drugs like Enhertu are just half-life extended chemo. Ranging from preclinical (PBS vs iso-DXd vs Ab-DXd) to clinical (different tox by Ab).

[SirtSix @SirtSix]

@XBIObserver Honestly, it's nice to see some conversation finally happening around anti-competitive bundling.

The practice of getting payors to grant formulary exclusivity for product A on the basis of discounts to other products B and C is ugly.

[SirtSix @SirtSix]

@curiouswavefn @Chemjobber 3. Comp to historical data

Looks like median RFS is ~18 months? Is that obviously better than other approaches (remember this is looking at the better prognosis set of PDAC patients whose disease is potentially resectable)?

[SirtSix @SirtSix]

@curiouswavefn @Chemjobber 2. Immortal time bias

The paper and most of the media on this study talk about the 16 patients whose tumor was resected, and went on to have adjuvant anti-PDL1 +vacccine.

A better denominator really seems like the 28 patients who underwent surgery.

[SirtSix @SirtSix]

But is it really?

The story could have just been titled ‘tumor suppressor mechanism, well… uh, suppresses tumors’.

The idea of telomere lengthening to extend lifespan has always been decisively middling at best.

[NYT Health @NYTHealth]

“Aging biology is a lot more complicated than we’d hoped.” https://t.co/khc0PVe1cX

[SirtSix @SirtSix]

@Biomaven Not like I am biased or anything… but that was not a great review.

Was hyper-focused on dismantling the SIR2 data in invertebrates and SIRT1 data in mice. But just spent two paragraphs on SIRT6, weirdly acknowledging Tg mice lived longer, but it didn’t matter for humans?

[SirtSix @SirtSix]

@Sanctuary_Bio $FHTX is def a guilty pleasure of mine. It is just refreshing to see a small company use their platform to develop against fairly novel targets. Would much rather have stake in someone being one of the first to target BRM, ARID1 or BRD9 than the fiftieth to target HER2 or CD19.

[SirtSix @SirtSix]

A tale as old as time... stock is trading cheap, science looks interesting, reasonable catalysts in the next 12 months.

[SirtSix @SirtSix]

@drug_smolecules What was the grade 5 AE?

[SirtSix @SirtSix]

@Biotenic Huh. TIL KIT is expressed in follicular melanocytes. And also in certain taste receptor cells important for umami and salt sensing.

[SirtSix @SirtSix]

@buysidebio Huh…TIL. Not an eye guy, but just seems weird - you bring someone in for a study visit, evaluate them, treat them, but wordsmith it so it’s like it didn’t happen.

[SirtSix @SirtSix]

Can someone smarter than me explain? I count five subjects receiving rescue injections, but $OCUL counts four?

[SirtSix @SirtSix]

@mopgcw And we’re just ignoring subject 2?